973 related articles for article (PubMed ID: 10918587)
21. The Shb adaptor protein binds to tyrosine 766 in the FGFR-1 and regulates the Ras/MEK/MAPK pathway via FRS2 phosphorylation in endothelial cells.
Cross MJ; Lu L; Magnusson P; Nyqvist D; Holmqvist K; Welsh M; Claesson-Welsh L
Mol Biol Cell; 2002 Aug; 13(8):2881-93. PubMed ID: 12181353
[TBL] [Abstract][Full Text] [Related]
22. Targeting the extracellular domain of fibroblast growth factor receptor 3 with human single-chain Fv antibodies inhibits bladder carcinoma cell line proliferation.
Martínez-Torrecuadrada J; Cifuentes G; López-Serra P; Saenz P; Martínez A; Casal JI
Clin Cancer Res; 2005 Sep; 11(17):6280-90. PubMed ID: 16144932
[TBL] [Abstract][Full Text] [Related]
23. Sustained phosphorylation of mutated FGFR3 is a crucial feature of genetic dwarfism and induces apoptosis in the ATDC5 chondrogenic cell line via PLCgamma-activated STAT1.
Harada D; Yamanaka Y; Ueda K; Nishimura R; Morishima T; Seino Y; Tanaka H
Bone; 2007 Aug; 41(2):273-81. PubMed ID: 17561467
[TBL] [Abstract][Full Text] [Related]
24. The role of tyrosine residues in fibroblast growth factor receptor 1 signaling in PC12 cells. Systematic site-directed mutagenesis in the endodomain.
Foehr ED; Raffioni S; Murray-Rust J; Bradshaw RA
J Biol Chem; 2001 Oct; 276(40):37529-36. PubMed ID: 11459840
[TBL] [Abstract][Full Text] [Related]
25. FRS2 proteins recruit intracellular signaling pathways by binding to diverse targets on fibroblast growth factor and nerve growth factor receptors.
Ong SH; Guy GR; Hadari YR; Laks S; Gotoh N; Schlessinger J; Lax I
Mol Cell Biol; 2000 Feb; 20(3):979-89. PubMed ID: 10629055
[TBL] [Abstract][Full Text] [Related]
26. Selective inhibition of fibroblast growth factor (FGF)-stimulated mitogenesis by a FGF receptor-1-derived phosphopeptide.
Dunican DJ; Williams EJ; Howell FV; Doherty P
Cell Growth Differ; 2001 May; 12(5):255-64. PubMed ID: 11373272
[TBL] [Abstract][Full Text] [Related]
27. Activation of FGF receptors by mutations in the transmembrane domain.
Li Y; Mangasarian K; Mansukhani A; Basilico C
Oncogene; 1997 Mar; 14(12):1397-406. PubMed ID: 9136983
[TBL] [Abstract][Full Text] [Related]
28. Perinuclear localization of the protein-tyrosine phosphatase SHP-1 and inhibition of epidermal growth factor-stimulated STAT1/3 activation in A431 cells.
Tenev T; Böhmer SA; Kaufmann R; Frese S; Bittorf T; Beckers T; Böhmer FD
Eur J Cell Biol; 2000 Apr; 79(4):261-71. PubMed ID: 10826494
[TBL] [Abstract][Full Text] [Related]
29. Ligand-independent activation of fibroblast growth factor receptor-2 by carboxyl terminal alterations.
Lorenzi MV; Castagnino P; Chen Q; Chedid M; Miki T
Oncogene; 1997 Aug; 15(7):817-26. PubMed ID: 9266968
[TBL] [Abstract][Full Text] [Related]
30. A novel type I fibroblast growth factor receptor activates mitogenic signaling in the absence of detectable tyrosine phosphorylation of FRS2.
Lopez ME; Korc M
J Biol Chem; 2000 May; 275(21):15933-9. PubMed ID: 10748122
[TBL] [Abstract][Full Text] [Related]
31. Reciprocal relationship in gene expression between FGFR1 and FGFR3: implication for tumorigenesis.
Jang JH
Oncogene; 2005 Jan; 24(5):945-8. PubMed ID: 15558020
[TBL] [Abstract][Full Text] [Related]
32. Interleukin 6 inhibits proliferation and, in cooperation with an epidermal growth factor receptor autocrine loop, increases migration of T47D breast cancer cells.
Badache A; Hynes NE
Cancer Res; 2001 Jan; 61(1):383-91. PubMed ID: 11196191
[TBL] [Abstract][Full Text] [Related]
33. FGFR3 isoforms have distinct functions in the regulation of growth and cell morphology.
Shimizu A; Takashima Y; Kurokawa-Seo M
Biochem Biophys Res Commun; 2002 Jan; 290(1):113-20. PubMed ID: 11779141
[TBL] [Abstract][Full Text] [Related]
34. Beta PDGF receptor mutants defective for mitogenesis promote neurite outgrowth in PC12 cells.
Vetter ML; Bishop JM
Curr Biol; 1995 Feb; 5(2):168-78. PubMed ID: 7743180
[TBL] [Abstract][Full Text] [Related]
35. Amino acid residues which distinguish the mitogenic potentials of two FGF receptors.
Wang JK; Goldfarb M
Oncogene; 1997 Apr; 14(15):1767-78. PubMed ID: 9150382
[TBL] [Abstract][Full Text] [Related]
36. Fibroblast growth factor receptors display both common and distinct signaling pathways.
Shaoul E; Reich-Slotky R; Berman B; Ron D
Oncogene; 1995 Apr; 10(8):1553-61. PubMed ID: 7731710
[TBL] [Abstract][Full Text] [Related]
37. Constitutively activated FGFR3 mutants signal through PLCgamma-dependent and -independent pathways for hematopoietic transformation.
Chen J; Williams IR; Lee BH; Duclos N; Huntly BJ; Donoghue DJ; Gilliland DG
Blood; 2005 Jul; 106(1):328-37. PubMed ID: 15784730
[TBL] [Abstract][Full Text] [Related]
38. The phosphotyrosine phosphatase SHP2 is a critical mediator of transformation induced by the oncogenic fibroblast growth factor receptor 3.
Agazie YM; Movilla N; Ischenko I; Hayman MJ
Oncogene; 2003 Oct; 22(44):6909-18. PubMed ID: 14534538
[TBL] [Abstract][Full Text] [Related]
39. In vitro biological characterization and antiangiogenic effects of PD 166866, a selective inhibitor of the FGF-1 receptor tyrosine kinase.
Panek RL; Lu GH; Dahring TK; Batley BL; Connolly C; Hamby JM; Brown KJ
J Pharmacol Exp Ther; 1998 Jul; 286(1):569-77. PubMed ID: 9655904
[TBL] [Abstract][Full Text] [Related]
40. Conditional activation of fibroblast growth factor receptor (FGFR) 1, but not FGFR2, in prostate cancer cells leads to increased osteopontin induction, extracellular signal-regulated kinase activation, and in vivo proliferation.
Freeman KW; Gangula RD; Welm BE; Ozen M; Foster BA; Rosen JM; Ittmann M; Greenberg NM; Spencer DM
Cancer Res; 2003 Oct; 63(19):6237-43. PubMed ID: 14559809
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
